These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
276 related items for PubMed ID: 22009113
1. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice. Bal SM, Slütter B, Verheul R, Bouwstra JA, Jiskoot W. Eur J Pharm Sci; 2012 Mar 12; 45(4):475-81. PubMed ID: 22009113 [Abstract] [Full Text] [Related]
2. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles? Slütter B, Bal SM, Que I, Kaijzel E, Löwik C, Bouwstra J, Jiskoot W. Mol Pharm; 2010 Dec 06; 7(6):2207-15. PubMed ID: 21043518 [Abstract] [Full Text] [Related]
3. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Slütter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Löwik C, Bouwstra J, Broere F, Jiskoot W. Vaccine; 2010 Aug 31; 28(38):6282-91. PubMed ID: 20638455 [Abstract] [Full Text] [Related]
4. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination. Slütter B, Jiskoot W. J Control Release; 2010 Nov 20; 148(1):117-121. PubMed ID: 20600405 [Abstract] [Full Text] [Related]
5. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Bal SM, Hortensius S, Ding Z, Jiskoot W, Bouwstra JA. Vaccine; 2011 Jan 29; 29(5):1045-52. PubMed ID: 21129393 [Abstract] [Full Text] [Related]
6. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. Bal SM, Slütter B, van Riet E, Kruithof AC, Ding Z, Kersten GF, Jiskoot W, Bouwstra JA. J Control Release; 2010 Mar 19; 142(3):374-83. PubMed ID: 19932723 [Abstract] [Full Text] [Related]
7. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJ, Jiskoot W. Vaccine; 2007 Jan 02; 25(1):144-53. PubMed ID: 16973248 [Abstract] [Full Text] [Related]
8. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination. Verheul RJ, Slütter B, Bal SM, Bouwstra JA, Jiskoot W, Hennink WE. J Control Release; 2011 Nov 30; 156(1):46-52. PubMed ID: 21784113 [Abstract] [Full Text] [Related]
9. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. Slütter B, Soema PC, Ding Z, Verheul R, Hennink W, Jiskoot W. J Control Release; 2010 Apr 19; 143(2):207-14. PubMed ID: 20074597 [Abstract] [Full Text] [Related]
10. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation. Bal SM, Slütter B, Jiskoot W, Bouwstra JA. Vaccine; 2011 May 23; 29(23):4025-32. PubMed ID: 21443959 [Abstract] [Full Text] [Related]
11. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. Boonyo W, Junginger HE, Waranuch N, Polnok A, Pitaksuteepong T. J Control Release; 2007 Aug 28; 121(3):168-75. PubMed ID: 17644205 [Abstract] [Full Text] [Related]
12. Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization. Liu Q, Zhang C, Zheng X, Shao X, Zhang X, Zhang Q, Jiang X. Vaccine; 2014 May 07; 32(22):2582-90. PubMed ID: 24681230 [Abstract] [Full Text] [Related]
13. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, Kündig TM, Gander B, Johansen P. J Control Release; 2010 Nov 01; 147(3):342-9. PubMed ID: 20727926 [Abstract] [Full Text] [Related]
14. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL, Heldens JG, van den Bosch H, Hennink WE, Jiskoot W. J Control Release; 2009 Dec 03; 140(2):126-33. PubMed ID: 19712713 [Abstract] [Full Text] [Related]
15. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S. Int J Pharm; 2008 Nov 03; 363(1-2):139-48. PubMed ID: 18662762 [Abstract] [Full Text] [Related]
16. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice. Huang CF, Wang CC, Wu TC, Chu CH, Peng HJ. Ann Allergy Asthma Immunol; 2007 Nov 03; 99(5):443-52. PubMed ID: 18051215 [Abstract] [Full Text] [Related]